Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.
Braun M, Aguilera AR, Sundarrajan A, Corvino D, Stannard K, Krumeich S, Das I, Lima LG, Meza Guzman LG, Li K, Li R, Salim N, Jorge MV, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Effern M, Quine B, Koufariotis LT, Casey M, Nakamura K, Seo EY, Hölzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes BGM, Wilmott JS, Long GV, Scolyer RA, Batstone MD, Landsberg J, Dietrich D, Pop OT, Flatz L, Dougall WC, Veillette A, Nicholson SE, Möller A, Johnston RJ, Martinet L, Smyth MJ, Bald T. Braun M, et al. Among authors: aguilera ar. Immunity. 2020 Oct 13;53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010. Immunity. 2020. PMID: 33053330 Free article.
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.
Blake SJ, Stannard K, Liu J, Allen S, Yong MC, Mittal D, Aguilera AR, Miles JJ, Lutzky VP, de Andrade LF, Martinet L, Colonna M, Takeda K, Kühnel F, Gurlevik E, Bernhardt G, Teng MW, Smyth MJ. Blake SJ, et al. Among authors: aguilera ar. Cancer Discov. 2016 Apr;6(4):446-59. doi: 10.1158/2159-8290.CD-15-0944. Epub 2016 Jan 19. Cancer Discov. 2016. PMID: 26787820
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.
Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ. Li XY, et al. Among authors: aguilera ar. J Clin Invest. 2018 Jun 1;128(6):2613-2625. doi: 10.1172/JCI98769. Epub 2018 May 14. J Clin Invest. 2018. PMID: 29757192 Free PMC article. Retracted.
Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.
Harjunpää H, Blake SJ, Ahern E, Allen S, Liu J, Yan J, Lutzky V, Takeda K, Aguilera AR, Guillerey C, Mittal D, Li XY, Dougall WC, Smyth MJ, Teng MWL. Harjunpää H, et al. Among authors: aguilera ar. Oncoimmunology. 2018 Mar 26;7(7):e1445949. doi: 10.1080/2162402X.2018.1445949. eCollection 2018. Oncoimmunology. 2018. PMID: 29900061 Free PMC article.
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.
Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, Scolyer RA, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ. Mittal D, et al. Among authors: aguilera ar. Cancer Immunol Res. 2019 Apr;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20. Cancer Immunol Res. 2019. PMID: 30894377 Free PMC article.
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.
Li XY, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera AR, Sundarrajan A, Jacoberger-Foissac C, Wong C, Dela Cruz T, Welch M, Lerner AG, Spatola BN, Soros VB, Corbin J, Anderson AC, Effern M, Hölzel M, Robson SC, Johnston RL, Waddell N, Smith C, Bald T, Geetha N, Beers C, Teng MWL, Smyth MJ. Li XY, et al. Among authors: aguilera ar. Cancer Discov. 2019 Dec;9(12):1754-1773. doi: 10.1158/2159-8290.CD-19-0541. Epub 2019 Nov 7. Cancer Discov. 2019. PMID: 31699796 Free PMC article.
ACKR4 restrains antitumor immunity by regulating CCL21.
Whyte CE, Osman M, Kara EE, Abbott C, Foeng J, McKenzie DR, Fenix KA, Harata-Lee Y, Foyle KL, Boyle ST, Kochetkova M, Aguilera AR, Hou J, Li XY, Armstrong MA, Pederson SM, Comerford I, Smyth MJ, McColl SR. Whyte CE, et al. Among authors: aguilera ar. J Exp Med. 2020 Jun 1;217(6):e20190634. doi: 10.1084/jem.20190634. J Exp Med. 2020. PMID: 32289156 Free PMC article.
The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation.
Ng SS, De Labastida Rivera F, Yan J, Corvino D, Das I, Zhang P, Kuns R, Chauhan SB, Hou J, Li XY, Frame TCM, McEnroe BA, Moore E, Na J, Engel JA, Soon MSF, Singh B, Kueh AJ, Herold MJ, Montes de Oca M, Singh SS, Bunn PT, Aguilera AR, Casey M, Braun M, Ghazanfari N, Wani S, Wang Y, Amante FH, Edwards CL, Haque A, Dougall WC, Singh OP, Baxter AG, Teng MWL, Loukas A, Daly NL, Cloonan N, Degli-Esposti MA, Uzonna J, Heath WR, Bald T, Tey SK, Nakamura K, Hill GR, Kumar R, Sundar S, Smyth MJ, Engwerda CR. Ng SS, et al. Among authors: aguilera ar. Nat Immunol. 2020 Oct;21(10):1205-1218. doi: 10.1038/s41590-020-0758-6. Epub 2020 Aug 24. Nat Immunol. 2020. PMID: 32839608 Free PMC article.
NKG7 Is Required for Optimal Antitumor T-cell Immunity.
Li XY, Corvino D, Nowlan B, Aguilera AR, Ng SS, Braun M, Cillo AR, Bald T, Smyth MJ, Engwerda CR. Li XY, et al. Among authors: aguilera ar. Cancer Immunol Res. 2022 Feb;10(2):154-161. doi: 10.1158/2326-6066.CIR-20-0649. Epub 2022 Jan 10. Cancer Immunol Res. 2022. PMID: 35013002
19 results